MATCHING-ADJUSTED INDIRECT TREATMENT COMPARISON AND SURVIVAL EXTRAPOLATION IN RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER (RAI-REFRACTORY DTC): UPDATED ANALYSIS

被引：2
|
作者：
Tremblay, G. [1 ]
Pelletier, C. [1 ]
Forsythe, A. [2 ]
Majethia, U. [2 ]
机构：
[1] Eisai, Woodcliff Lake, NJ USA
[2] Eisai Inc, Woodcliff Lake, NJ USA
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.1048
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN33
引用
收藏
页码：A435 / A435
页数：1
相关论文
共 50 条
  • [1] MATCHING-ADJUSTED INDIREC TREATMENT COMPARISON AND SURVIVAL EXTRAPOLATION IN RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER (RAI-REFRACTORY DTC)
    Tremblay, G.
    Holbrook, T.
    Milligan, G.
    Pelletier, C.
    VALUE IN HEALTH, 2015, 18 (03) : A11 - A11
  • [2] Targeted therapy in patients with radioiodine-refractory differentiated thyroid cancer (DTC)
    Herceg, Davorin
    Herceg, Gordana Horvatic
    PERIODICUM BIOLOGORUM, 2014, 116 (04) : 399 - 407
  • [3] Response to lenvatinib treatment in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC)
    Gianoukakis, Andrew G.
    Mathias, Elton
    Dutcus, Corina E.
    Young, Louise
    Kalantari, Parmida
    Yoon, Steve
    CLINICAL ENDOCRINOLOGY, 2017, 86 : 68 - 68
  • [4] Response to Lenvatinib treatment in patients with Radioiodine-refractory Differentiated Thyroid Cancer (RR-DTC)
    Gianoukakis, A. G.
    Mathias, E.
    Dutcus, C. E.
    Kalantari, P.
    Yoon, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 307 - 307
  • [5] THE EVPI OF TREATMENT STRATEGIES FOR RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER
    Huang, W.
    Chen, L.
    Ting, J.
    Cao, V
    Sung, H.
    Yokokura, M.
    Wilson, L.
    VALUE IN HEALTH, 2016, 19 (07) : A886 - A886
  • [6] Sorafenib in the treatment of radioiodine-refractory differentiated thyroid cancer: a meta-analysis
    Shen, Chen-Tian
    Qiu, Zhong-Ling
    Luo, Quan-Yong
    ENDOCRINE-RELATED CANCER, 2014, 21 (02) : 253 - 261
  • [7] Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid carcinoma: a systematic review and indirect comparison with sorafenib
    Kawalec, Pawel
    Malinowska-Lipien, Iwona
    Brzostek, Tomasz
    Kozka, Maria
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (12) : 1303 - 1309
  • [8] Treatment of Patients with Radioiodine-Refractory, differentiated Thyroid Cancer A Consensus Statement
    Lindner, C.
    Dierneder, J.
    Pall, G.
    Pirich, C.
    Hoffmann, M.
    Raderer, M.
    Becherer, A.
    Niederle, B.
    Lipp, R.
    Lind, P.
    Gallowitsch, H.
    Romeder, F.
    Virgolini, I.
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2015, 54 (03): : 125 - 130
  • [9] Response to lenvatinib treatment in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC): Updated results from SELECT.
    Gianoukakis, Andrew G.
    Mathias, Elton George
    Dutcus, Corina
    Kalantari, Parmida
    Yoon, Steve
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [10] Sorafenib and radioiodine-refractory differentiated thyroid cancer (RR-DTC): a systematic review and meta-analysis
    Feng, Guoli
    Luo, Yi
    Zhang, Qi
    Zeng, Feng
    Xu, Jie
    Zhu, Jingqiang
    ENDOCRINE, 2020, 68 (01) : 56 - 63
12345